How Low-Dose Methotrexate Reduces Inflammation
Author Information
Author(s): Montesinos M Carmen, Desai Avani, Cronstein Bruce N
Primary Institution: New York University School of Medicine
Hypothesis
The study investigates whether the anti-inflammatory effects of low-dose methotrexate are mediated by adenosine A2A and A3 receptor activation in a mouse model of peritoneal inflammation.
Conclusion
The study concludes that low-dose methotrexate reduces inflammation primarily through adenosine A2A receptor activation, while A3 receptor activation does not play a significant role.
Supporting Evidence
- Methotrexate treatment increased adenosine concentration in the peritoneal exudates of all mice studied.
- Leukocyte accumulation was reduced in wild-type and A3 receptor knockout mice but not in A2A receptor knockout mice.
- Methotrexate reduced TNF-α levels in wild-type and A3 receptor knockout mice but not in A2A receptor knockout mice.
- IL-10 levels increased in methotrexate-treated wild-type and A3 knockout mice but decreased in A2A knockout mice.
Takeaway
This study shows that a medicine called methotrexate helps reduce swelling in the body by working with a special helper called adenosine, but it only needs one type of adenosine helper to do its job.
Methodology
Mice were treated with low-dose methotrexate and their peritoneal inflammation was induced using thioglycollate, followed by analysis of leukocyte accumulation and cytokine levels.
Limitations
The study's findings may not be directly applicable to human inflammatory conditions due to the use of a specific mouse model.
Participant Demographics
Mice used in the study included wild-type, A2A receptor knockout, and A3 receptor knockout strains.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website